[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
November 6, 2013

β-Blockers as Initial Therapy for Hypertension

Author Affiliations
  • 1Centre for Evidence-Based Health Care, Stellenbosch University, Cape Town, South Africa
  • 2Hatter Institute for Cardiovascular Research in Africa, University of Cape Town Medical School, Cape Town, South Africa
JAMA. 2013;310(17):1851-1852. doi:10.1001/jama.2013.277510
Abstract

Clinical Question  Are β-blockers associated with lower rates of all-cause mortality and cardiovascular events when used as initial treatment in individuals with hypertension compared with placebo, no treatment, or other drugs?

Bottom Line  Initial therapy of hypertension with β-blockers is not associated with reduced all-cause mortality but is associated with modest reductions in cardiovascular events compared with placebo or no treatment. Calcium channel blockers and renin-angiotensin system inhibitors are associated with greater reductions in cardiovascular event rates than β-blockers. This evidence derives from trials of traditional β-blockers (eg, atenolol and propranolol), because there are currently no mortality and cardiovascular event data on the new vasodilating β-blockers (eg, carvedilol and nebivolol).

×